Treating multiple sclerosis with monoclonal antibodies: a 2010 update.
about
Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosisChloroquine treatment enhances regulatory T cells and reduces the severity of experimental autoimmune encephalomyelitisMOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcomeProgressive multiple sclerosis: from pathogenic mechanisms to treatment.Efficacy and safety of alemtuzumab in multiple sclerosis and impact on nursing role.Treating multiple sclerosis with monoclonal antibodies: a 2013 update.A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis.Multiple sclerosis therapeutic pipeline: opportunities and challenges.Novel treatment for immune neuropathies on the horizon.Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis.Monoclonal antibodies in neuroinflammatory diseases.MS4A Cluster in Alzheimer's Disease.Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management.Anti-MS4a4B treatment abrogates MS4a4B-mediated protection in T cells and ameliorates experimental autoimmune encephalomyelitis.CD98 is a potential target for ablating B cell clonal expansion and autoantibody in multiple sclerosis.Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry.Cytokine Profile in Patients with Progressive Multiple Sclerosis and Its Association with Disease Progression and Disability.
P2860
Q28484467-F25A8FBA-BC63-4308-99A9-C7D302BF43F5Q28533957-0858CF39-0957-4CED-82EE-E622DFB7FDAFQ30371412-8FC62A42-6236-4C4C-B73C-6B8AF1EC4CA3Q31139925-724A16B7-F3F4-43BB-9AF7-4510C17AA951Q33412834-20E08B03-9ECD-4BD9-8EF2-D766C9FCCF11Q34330211-FAC65A31-E043-4ED9-BC89-05A3CAA4D9DCQ36960355-E9ACE5ED-74FA-40F5-901A-E93BD73871BCQ37800214-3BDD6EAC-6E62-48B3-BC23-7511A6FEA9F5Q37855722-925E9F23-3618-449D-B675-DE72C8633CC4Q37892641-7064D590-95C8-48CB-8DAE-7A6D9F88F6AEQ37997089-4EEAF31C-C418-4621-8B65-28129B3E5F23Q38092121-65957218-2BBC-4ACB-8256-D29EB615F864Q38224993-2005A009-A12F-462F-84B1-E3EF344DA76BQ38690022-FD6338E7-6FD8-47EF-A336-074E5249640EQ39134948-EE53D9B5-3129-49D3-904E-FF270B18E7E7Q41820142-B5334104-64EC-4EFD-8A54-F3E04361B520Q48224174-6ED0C85F-58D7-4548-A99E-8CD6BBDC1E2AQ52143402-F2A1BFE8-F03A-4C3A-A9CC-2A975FA9E844
P2860
Treating multiple sclerosis with monoclonal antibodies: a 2010 update.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Treating multiple sclerosis with monoclonal antibodies: a 2010 update.
@en
Treating multiple sclerosis with monoclonal antibodies: a 2010 update.
@nl
type
label
Treating multiple sclerosis with monoclonal antibodies: a 2010 update.
@en
Treating multiple sclerosis with monoclonal antibodies: a 2010 update.
@nl
prefLabel
Treating multiple sclerosis with monoclonal antibodies: a 2010 update.
@en
Treating multiple sclerosis with monoclonal antibodies: a 2010 update.
@nl
P2860
P356
P1476
Treating multiple sclerosis with monoclonal antibodies: a 2010 update
@en
P2093
Mathias Buttmann
P2860
P304
P356
10.1586/ERN.10.38
P577
2010-05-01T00:00:00Z